267
Participants
Start Date
November 17, 2013
Primary Completion Date
June 28, 2017
Study Completion Date
June 28, 2019
Venetoclax
Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
Cyclophosphamide
Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
Obinutuzumab
Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
Rituximab
Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.
Doxorubicin
Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Vincristine
Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Prednisone
Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
Semmelweis Egyetem, Budapest
Medizinische Universität Wien, Vienna
Orszagos Onkologiai Intezet, Budapest
Concord Repatriation General Hospital, Concord
Peter MacCallum Cancer Centre-East Melbourne, Melbourne
Royal Melbourne Hospital, Parkville
Debreceni Egyetem; Belgyogyaszati Klinika Hematologiai Tanszek, Debrecen
Princess Alexandra Hospital, Woolloongabba
LKH - Universitätsklinikum der PMU Salzburg, Salzburg
Memorial Sloan-Kettering Cancer Center, New York
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin
Uni of Rochester Medical Center; Wilmot Cancer Center, Pharmacy Department, Rochester
Azienda Ospedaliero Universitaria San Martino, Genoa
Hospital Universitario Ramon y Cajal, Madrid
Hopital Saint Eloi, Montpellier
CHU Rennes - Hopital Pontchaillou, Rennes
Hospital Universitario de Salamanca, Salamanca
Tennessee Oncology, Nashville
CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation, Nantes
Hôpital de Brabois Adultes, Vandœuvre-lès-Nancy
Azienda Ospedaliero Universitaria Pisana; U.O. Farmaceutica, Pisa
Hopital Claude Huriez - CHU Lille, Lille
The West Clinici, St Louis
Centre Hospitalier Lyon Sud, Pierre-Bénite
Clinique Victor Hugo; Pharmacie, Le Mans
Hôpital Saint-Louis, Paris
Centre Henri Becquerel; Hematologie, Rouen
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli
Centre Hospitalier Départemental Les Oudairies, La Roche-sur-Yon
San Juan Oncology Associates, Farmington
UCLA Jonsson Comprehensive Cancer Center, Los Angeles
Azienda Ospedaliera Vincenzo Cervello, Palermo
St. Jude Heritage Healthcare, Fullerton
Central Coast Medical Oncology, Santa Maria
Hopital Henri Mondor, Unite Hemopathies lymphoides, Créteil
Hospital Universitario La Paz, Madrid
Hackensack University Medical Center; WFAN - Imus Pediatric Center, Hackensack
Cross Cancer Institute, Edmonton
BC Cancer Agency, CSI, Kelowna
BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency, Vancouver
Jewish General Hospital; Research Unit, Montreal
CHU de Quebec - Hôpital de l' Enfant Jésus, Québec
Fakultni nemocnice Brno, Brno
Fakultni nemocnice Hradec Kralove, Hradec Králové
Fakultni nemocnice Ostrava, Ostrava - Poruba
Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Prague
Amsterdam UMC Location VUMC, Amsterdam
Erasmus Medisch Centrum, Rotterdam
UMC Utrecht, Utrecht
Hospital del Mar, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
ICO l´Hospitalet - Hospital Duran i Reynals; Hematology, Barcelona
Collaborators (1)
AbbVie
INDUSTRY
Hoffmann-La Roche
INDUSTRY